📊 Evidence-Based Reference

Ekos Endovascular Device

Boston Scientific Corporation

Contact a rep Compare similar devices

Summary: The EKOS Endovascular Device, manufactured by Boston Scientific, is primarily used for mechanical thrombectomy in venous applications. Key evidence highlights its use in ultrasound-assisted thrombolysis for conditions like pulmonary embolism.

FDA Clearance Information

Pathway ? 510(k)
Number ? K220866 ↗
Decision Date ? April 20, 2022
Product Code ? QEY Mechanical Thrombolysis Catheter
Device Class ? Class 2
Evidence ? 35 studies

The EKOS Endovascular Device was cleared by the FDA via the 510(k) pathway on April 20, 2022. It is manufactured by Boston Scientific and classified as a Class 2 device.

What It Is

The EKOS Endovascular Device is a catheter-based system designed to enhance thrombolysis through ultrasound assistance. It is intended for use in the treatment of venous thromboembolic conditions, facilitating the breakdown of blood clots.

FDA-Cleared Indications

  • Used to facilitate the infusion of thrombolytic agents into blood clots in the peripheral vasculature.
  • Used to facilitate the infusion of thrombolytic agents into pulmonary emboli.
  • Used with thrombolytic medication to assist clot dissolution in appropriately selected patients.

Clinical Applications

  • Catheter-directed, ultrasound-assisted thrombolysis for selected pulmonary embolism.
  • Catheter-directed treatment of selected lower-extremity deep vein thrombosis.
  • Treatment of venous thromboembolism when targeted thrombolytic infusion is clinically appropriate.
  • Use during image-guided endovascular procedures in which a thrombolytic agent is delivered directly into a clot.

Reported off-label uses

  • Use in selected thrombosed dialysis grafts or fistulas as part of catheter-directed thrombolysis or thrombectomy strategies.
  • Use in other peripheral venous thromboses not specifically covered by the device's cleared labeling.

Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.

Evidence Summary

The literature includes 15 studies, comprising RCTs, prospective, and retrospective analyses, published between 2022 and 2025. These studies explore the device's efficacy and safety in various thromboembolic conditions.

Reported Outcomes

Published studies report that the EKOS Endovascular Device is effective in enhancing thrombolysis, particularly in pulmonary embolism cases. Outcomes include improved rates of clot resolution and limb salvage, with some studies noting sex-based differences in efficacy.

Safety Profile

Reported complications include bleeding events and potential device-related adverse effects. However, the overall safety profile is considered favorable in comparison to systemic thrombolysis.

Evidence Limitations

Evidence gaps include a need for larger, long-term studies to better understand the device's efficacy across diverse patient populations. Current studies often have limited sample sizes and short follow-up durations.

Practical Considerations

  • The system is used with a compatible catheter, guidewire, ultrasound-control equipment and a prescribed thrombolytic medication; the device does not dissolve clot without medication.
  • Access is commonly obtained through a peripheral venous site, such as the femoral or popliteal vein, depending on the clot location and treatment plan.
  • Available catheter configurations and working lengths vary; the treating team must match catheter size, length and infusion segment to the vessel and clot anatomy.
  • Patients require careful assessment for bleeding risk, including recent surgery, active bleeding, intracranial hemorrhage, severe uncontrolled hypertension and other contraindications to thrombolytic therapy.
  • MRI compatibility depends on the specific catheter and system configuration. The exact device labeling should be checked before MRI, and the catheter should not be assumed to be safe in the scanner.

Procedures that use this device

Linked Studies (20)

PubMed • 2026

Real-world clinical outcomes of EKOS catheter-directed thrombolysis versus systemic alteplase in acute pulmonary embolism: a retrospective cohort study.

Frontiers in pharmacology

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025

Novel Phase Shift Microbubbles, MVT-101, Enhance Sonothrombolysis in a Porcine Model of Deep Vein Thrombosis.

Nanotheranostics

View Source →
PubMed • 2024

[Interventional therapy of pulmonary embolism - update].

Deutsche medizinische Wochenschrift (1946)

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

Initiating and imaging cavitation from infused echo contrast agents through the EkoSonic catheter.

Scientific reports

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

[Ultrasound-accelerated thrombolysis. Initial experience in patients with contraindications to systemic thrombolysis].

Revista medica del Instituto Mexicano del Seguro Social

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

Quantifying the Effect of Acoustic Parameters on Temporal and Spatial Cavitation Activity: Gauging Cavitation Dose.

Ultrasound in medicine & biology

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Treatment With EkoSonic™ Endovascular System (EKOS®) of Massive Pulmonary Thrombosis Following Recovery From COVID-19 Infection.

Cureus

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

EkoSonic™ Endovascular System-Directed Thrombolysis in a Patient With COVID-19 Infection Presenting With Bilateral Large Pulmonary Embolism Causing Right Ventricular Strain: A Case Report.

Cureus

Case Report View Source →
PubMed • 2022

Analysis of pulmonary embolism patients treated with EkoSonic™ endovascular system.

Turk gogus kalp damar cerrahisi dergisi

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Successful Thrombolysis of Acute Upper Limb Ischemia Using Ekosonic Endovascular System Ultrasound Catheter in a Patient With Atrial Fibrillation.

Cardiovascular revascularization medicine : including molecular interventions

Case Series View Source →
PubMed • 2022

Stability of alteplase for ultrasound-facilitated catheter-directed thrombolysis.

Blood advances

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Massive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital.

Journal of thrombosis and thrombolysis

Case Series View Source →
PubMed • 2022

EKOS™ Jena Experience: Safety, Feasibility, and Midterm Outcomes of Percutaneous Ultrasound-Assisted Catheter-Directed Thrombolysis in Patients with Intermediate-High-Risk or High-Risk Pulmonary Embolism.

Canadian respiratory journal

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2021

Cavitation Emissions Nucleated by Definity Infused through an EkoSonic Catheter in a Flow Phantom.

Ultrasound in medicine & biology

View Source →
PubMed • 2021

Hemodynamic Effects of Ultrasound-Assisted, Catheter-Directed, Very Low-Dose, Short-Time Duration Thrombolysis in Acute Intermediate-High Risk Pulmonary Embolism (from the EKOS-PL Study).

The American journal of cardiology

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2020

Ekosonic Endovascular System (EKOS) in a trauma patient with intracranial bleed, recent major surgery, and massive pulmonary embolus: A case report.

Radiology case reports

Case Report View Source →
PubMed • 2020

EkoSonic Thrombolysis as a Therapeutic Adjunct in Venous Occlusive Disease.

The International journal of angiology : official publication of the International College of Angiology, Inc

Retrospective|case Series View Source →
PubMed • 2020

The Role of EkoSonic Endovascular System or EKOS® in Pulmonary Embolism.

Cureus

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2020

EkoSonic® endovascular system and other catheter-directed treatment reperfusion strategies for acute pulmonary embolism: overview of efficacy and safety outcomes.

Expert review of medical devices

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2020

Real-World Outcomes of EKOS Ultrasound-Enhanced Catheter-Directed Thrombolysis for Acute Limb Ischemia.

Annals of vascular surgery

RCT|prospective|retrospective|case Series|other View Source →

Frequently Asked Questions

What are the clinical indications for EKOS Endovascular Device?

The device is indicated for use in mechanical thrombectomy for venous thromboembolic conditions, such as pulmonary embolism and deep vein thrombosis.

What outcomes have been reported in clinical studies?

Clinical studies have reported effective clot resolution and improved limb salvage rates, with some variations based on patient demographics.

What complications have been reported?

Safety data indicate bleeding events as a primary complication, though the device is generally considered safe compared to systemic thrombolysis.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you